| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2022: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2021: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Outline of Final Research Achievements |
Cases and samples were collected, and measurements and experiments were performed using the samples. Some results of the obtained clinical study (case study) part were reported in Shinshu Med J. 2022 70(1):29-38. It was suggested that treatment of patients with AL amyloidosis with a proteasome inhibitor-based chemotherapy regimen followed by a lenalidomide (immunomodulatory drug, IMIDs)-based chemotherapy regimen results in better outcomes than conventional treatment. The importance of sufficient reduction of the amyloid precursor protein (free light chain) concentration in the patient's blood by administering a proteasome inhibitor before performing lenalidomide-based regimen was suggested.
|
